Cytek Biosciences, Inc. President and CEO Wenbin Jiang filed a Form 4 on November 20, 2026, reporting multiple restricted stock unit vesting events and related tax-withholding share disposals that took place on November 18, 2026.
Key Highlights
- Four RSU tranches vested: Jiang converted 11,781, 22,100, 29,002, and 57,212 restricted stock units into common shares on November 18, 2026, according to the filing.
- Shares withheld for taxes: The issuer withheld 4,636, 8,697, 11,413, and 22,513 shares, respectively, at $5.92 per share to satisfy tax withholding obligations.
- Resulting beneficial ownership: Following all transactions, Jiang directly held 5,633,865 shares of common stock, the filing disclosed.
- Remaining RSU balances: After the vesting events, Jiang held 15,713, 117,873, 270,692, and 762,842 RSUs outstanding across four separate award tranches.
- Role: Jiang is identified in the filing as both a Director and President and CEO of Cytek Biosciences, listed on NASDAQ:CTKB.
Jiang RSU Vesting and Tax Withholding Details for Cytek Biosciences
According to the Form 4 filed with the SEC, Wenbin Jiang, President and CEO of Cytek Biosciences, Inc. (NASDAQ:CTKB), reported four separate restricted stock unit vesting transactions on November 18, 2026. Each restricted stock unit represents, per the filing, "a contingent right to receive one share of the Issuer's common stock." The four tranches that vested were 11,781 shares, 22,100 shares, 29,002 shares, and 57,212 shares, all coded as "M" transactions in the filing, indicating conversion of derivative securities.
Concurrent with each vesting event, the filing reported that shares were withheld by the issuer to cover tax obligations. The filing states these represent "the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award." The withheld amounts were 4,636, 8,697, 11,413, and 22,513 shares respectively, each at a price of $5.92 per share. All transactions were coded "F," designating payment of exercise price or tax liability using securities.
The four RSU awards carry staggered four-year vesting schedules beginning in different years. The earliest tranche began vesting in May 2023, the second in May 2024, the third in May 2025, and the most recent in May 2026. Each schedule involves fractional vesting at multiple dates across the year. After all reported transactions, the filing indicates Jiang's remaining RSU balances were 15,713, 117,873, 270,692, and 762,842 units across the four respective awards. All share holdings and RSU positions are reported as directly owned.
What Was Disclosed
Wenbin Jiang, President and CEO of Cytek Biosciences, reported vesting of four RSU tranches totaling 120,095 shares on November 18, 2026, with 47,259 shares withheld at $5.92 for taxes, leaving direct beneficial ownership of 5,633,865 common shares.




Please wait processing your request...